Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Pulse power: beans and lentils may reshape your gut bacteria

NCT ID NCT07043712

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how eating a diet rich in pulses—like beans, lentils, and peas—affects the gut microbiome, feelings of fullness, and appetite hormones. Researchers are enrolling 44 overweight or obese adults who will follow a high-pulse diet for four weeks. The goal is to see if these foods can positively change gut bacteria and help with appetite control, which could be useful for managing metabolic syndrome.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
high pulse diet (beans, lentils, peas, chickpeas)
What this could lead to
If successful, this could show that eating more pulses helps improve gut health and appetite control, pointing toward dietary strategies for managing metabolic syndrome.
What could go wrong
This is a small, early-stage dietary study with only 44 participants. Results may not apply to everyone, and the diet may be hard to follow long-term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 44 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men and women (premenopausal only) * Age 20-55y (we will attempt to start baseline testing at the same time of the menstrual cycle (luteal) for the women * BMI ≥25 or ≤40 kg/m2 (most at risk for metabolic abnormalities and will benefit from a pulse intervention-2/3 of Americans are overweight or obese) * Weight stable (no fluctuations in body weight of greater than 4 kg in the last 3 months) * Willing to consume a research diet * Willing to provide blood and fecal samples * Sedentary to low active physical activity status (less than 7200 steps per day) * Stably treated with statin drugs, anti-hypertensives, and anti-depressants. These are acceptable as long as the drug category does not alter appetite, body weight, or the microbiome (if known) * Pre-diabetes acceptable (glucose \<125 mg/dL or HbA1c \< 6.5%) * At least one characteristic of the metabolic syndrome (but not diabetic) 1. A large waistline: 35 inches or more for women 40 inches or more for men 2. High triglycerides: 150 mg/dL or higher 3. Low HDLc level: \<50 mg/dL for women \<40 mg/dL for men 4. High blood pressure ≥130/85 mmHg 5. Fasting blood sugar ≥100 mg/dL - Pre-diabetes acceptable (glucose \<125 mg/dL or HbA1c \<6.5%) - Exclusion Criteria: * Pregnant or lactating * Postmenopausal (evidence suggests an interplay between the gut microbiome) * BMI of \<25 or \>40 kg/m2 * Use of medications that affect the gut microbiome (e.g. antibiotics) * Taking medications known to affect appetite (e.g., phentermine) or gastrointestinal function (e.g., metformin) * On a special diet or undergoing weight loss, vegetarian, or other restricted dietary patterns * Ad libitum intake of fiber above 25g/day (mean intake in the US population is 17g/day) and \< 10g/d * History of disease (example colon cancer, HIV, cardiovascular disease, psychiatric disorders, etc.) * Use of tobacco products

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Missouri

    Columbia, Missouri, 65212, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.